S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

IntelliPharmaCeutics Intl Stock Price, News & Analysis (OTCMKTS:IPCIF)

$0.11
-0.01 (-8.25 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$0.11
Now: $0.11
$0.13
50-Day Range
$0.12
MA: $0.19
$0.23
52-Week Range
$0.11
Now: $0.11
$0.36
Volume151,385 shs
Average Volume114,680 shs
Market Capitalization$2.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPCIF
CUSIPN/A
Phone416-798-3001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.71 million
Book Value($0.11) per share

Profitability

Net Income$-13,750,000.00
Net Margins-289.69%

Miscellaneous

EmployeesN/A
Market Cap$2.43 million
Next Earnings Date10/21/2019 (Estimated)
OptionableOptionable

Receive IPCIF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPCIF and its competitors with MarketBeat's FREE daily newsletter.


IntelliPharmaCeutics Intl (OTCMKTS:IPCIF) Frequently Asked Questions

What is IntelliPharmaCeutics Intl's stock symbol?

IntelliPharmaCeutics Intl trades on the OTCMKTS under the ticker symbol "IPCIF."

When did IntelliPharmaCeutics Intl's stock split? How did IntelliPharmaCeutics Intl's stock split work?

Shares of IntelliPharmaCeutics Intl reverse split before market open on Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of IntelliPharmaCeutics Intl stock prior to the reverse split would have 10 shares after the split.

How were IntelliPharmaCeutics Intl's earnings last quarter?

IntelliPharmaCeutics Intl Inc (OTCMKTS:IPCIF) released its earnings results on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.70). The business had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.90 million. IntelliPharmaCeutics Intl had a negative net margin of 289.69% and a negative return on equity of 2,640.60%. View IntelliPharmaCeutics Intl's Earnings History.

When is IntelliPharmaCeutics Intl's next earnings date?

IntelliPharmaCeutics Intl is scheduled to release their next quarterly earnings announcement on Monday, October 21st 2019. View Earnings Estimates for IntelliPharmaCeutics Intl.

What price target have analysts set for IPCIF?

1 brokers have issued 12-month target prices for IntelliPharmaCeutics Intl's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate IntelliPharmaCeutics Intl's share price to reach $6.00 in the next year. This suggests a possible upside of 5,349.6% from the stock's current price. View Analyst Price Targets for IntelliPharmaCeutics Intl.

What is the consensus analysts' recommendation for IntelliPharmaCeutics Intl?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelliPharmaCeutics Intl in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelliPharmaCeutics Intl.

Has IntelliPharmaCeutics Intl been receiving favorable news coverage?

News coverage about IPCIF stock has been trending negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IntelliPharmaCeutics Intl earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for IntelliPharmaCeutics Intl.

Who are some of IntelliPharmaCeutics Intl's key competitors?

What other stocks do shareholders of IntelliPharmaCeutics Intl own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelliPharmaCeutics Intl investors own include Brainstorm Cell Therapeutics (BCLI), Eyepoint Pharmaceuticals (EYPT), Biocept (BIOC), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Geron (GERN), Inovio Pharmaceuticals (INO), CytRx (CYTR), Anavex Life Sciences (AVXL) and SCYNEXIS (SCYX).

Who are IntelliPharmaCeutics Intl's key executives?

IntelliPharmaCeutics Intl's management team includes the folowing people:
  • Dr. Isa Odidi, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 61)
  • Dr. Amina Odidi, Pres, COO, Co-Chief Scientist Officer & Director (Age 59)
  • Mr. Greg Powell, Chief Financial Officer

How do I buy shares of IntelliPharmaCeutics Intl?

Shares of IPCIF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IntelliPharmaCeutics Intl's stock price today?

One share of IPCIF stock can currently be purchased for approximately $0.11.

How big of a company is IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl has a market capitalization of $2.43 million and generates $1.71 million in revenue each year. View Additional Information About IntelliPharmaCeutics Intl.

What is IntelliPharmaCeutics Intl's official website?

The official website for IntelliPharmaCeutics Intl is http://www.intellipharmaceutics.com/.

How can I contact IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]


MarketBeat Community Rating for IntelliPharmaCeutics Intl (OTCMKTS IPCIF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe IPCIF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCIF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel